| Literature DB >> 33654186 |
Ken-Ichiro Konishi1,2, Tatsuki Mizuochi3, Hajime Takei4, Ryosuke Yasuda1, Hirotaka Sakaguchi1, Jun Ishihara1, Yugo Takaki1, Masahiro Kinoshita1, Naoki Hashizume5, Suguru Fukahori5, Hiromichi Shoji6, Go Miyano7, Koichiro Yoshimaru8, Toshiharu Matsuura8, Yukihiro Sanada9, Takahisa Tainaka10, Hiroo Uchida10, Yumiko Kubo11, Hiromu Tanaka11, Hideyuki Sasaki11, Tsuyoshi Murai12, Jun Fujishiro2, Yushiro Yamashita1, Masaki Nio11, Hiroshi Nittono4, Akihiko Kimura1.
Abstract
Diagnosis of biliary atresia (BA) can involve uncertainties. In the present prospective multicenter study, we considered whether urinary oxysterols represent a useful marker for diagnosis of BA in Japanese children. Subjects under 6 months old at 7 pediatric centers in Japan were prospectively enrolled, including patients with cholestasis and healthy controls (HC) without liver disease. Patients with cholestasis constituted 2 groups representing BA patients and others with cholestasis from other causes (non-BA). We quantitatively analyzed 7 oxysterols including 4β-, 20(S)-, 22(S)-, 22(R)-, 24(S)-, 25-, and 27-hydroxycholesterol by liquid chromatography/electrospray ionization-tandem mass spectrometry. Enrolled subjects included 14 with BA (median age 68 days; range 26-170) and 10 non-BA cholestatic controls (59; 14-162), as well as 10 HC (57; 25-120). Total urinary oxysterols were significantly greater in BA (median, 153.0 μmol/mol creatinine; range 24.1-486.7; P < 0.001) and non-BA (36.2; 5.8-411.3; P < 0.05) than in HC (2.7; 0.8-7.6). In patients with BA, urinary 27-hydroxycholesterol (3.61; 0.42-11.09; P < 0.01) was significantly greater than in non-BA (0.71; 0-5.62). In receiver operating characteristic (ROC) curve analysis for distinguishing BA from non-BA, the area under the ROC curve for urinary 27-hydroxycholesterol was 0.83. In conclusion, this first report of urinary oxysterol analysis in patients with BA indicated that 27-hydroxycholesterol may be a useful marker for distinguishing BA from other causes of neonatal cholestasis.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33654186 PMCID: PMC7925559 DOI: 10.1038/s41598-021-84445-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379